OOIR: Observatory of International Research

Papers

(The H4-Index of AIDS is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Characteristics and outcomes of COVID-19 in patients with HIV: a multicentre research network study	120
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis	90
Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study	89
Viral suppression rates in a safety-net HIV clinic in San Francisco destabilized during COVID-19	74
Disproportionate burden of coronavirus disease 2019 among racial minorities and those in congregate settings among a large cohort of people with HIV	72
Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV	70
Risk of adverse coronavirus disease 2019 outcomes for people living with HIV	67
HIV infection and COVID-19: risk factors for severe disease	62
Impaired antibody response to COVID-19 vaccination in advanced HIV infection	58
The Joint United Nations Programme on HIV/AIDS 95–95–95 targets: worldwide clinical and cost benefits of generic manufacture	54
Incident HIV among pregnant and breast-feeding women in sub-Saharan Africa: a systematic review and meta-analysis	51
Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy – naive adults with HIV-1 infection	49
The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen	46
HIV in Iran: onset, responses, and future directions	46
Productive HIV infection in astrocytes can be established via a nonclassical mechanism	40
Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes	40
Coronavirus disease 2019 and Pneumocystis jirovecii pneumonia: a diagnostic dilemma in HIV	40
Population-level effectiveness of a national HIV preexposure prophylaxis programme in MSM	37
Clinical characteristics, comorbidities and outcomes among persons with HIV hospitalized with coronavirus disease 2019 in Atlanta, Georgia	37
Safety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV	37
Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment	36
Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV	36
Risk factors for loss to follow-up from antiretroviral therapy programmes in low-income and middle-income countries	34
The People Living with HIV Stigma Index 2.0: generating critical evidence for change worldwide	34
Antiretroviral drug concentrations in brain tissue of adult decedents	34

Community-based delivery of HIV treatment in Zambia: costs and outcomes	34
TIGIT is upregulated by HIV-1 infection and marks a highly functional adaptive and mature subset of natural killer cells	33
Worldwide relative smoking prevalence among people living with and without HIV	33
Mortality and causes of death in people living with HIV in the era of combination antiretroviral therapy compared with the general population in Japan	32
Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen	31
Oral preexposure prophylaxis continuation, measurement and reporting	30
Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials	30